Symplocin A, a Linear Peptide from the Bahamian Cyanobacterium Symploca sp. Configurational Analysis of N,N-Dimethylamino Acids by Chiral-Phase HPLC of Naphthacyl Esters

Molinski, Tadeusz F.; Reynolds, Kirk A.; Morinaka, Brandon I.

doi:10.1021/np200861n

Cited by 37 publications

(36 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 An analog of dolastatin 10, TZT-1027 (auristatin PE or soblidotin), which differs from dolastatin 10 only in the absence of the thiazoline ring from the dolaphenine residue, was found to be effective in two human xenograft models, MX-1 breast carcinoma and LX-1 lung carcinoma in mice. 29 It showed equivalent efficacy against both p53 normal and mutant cell lines, 30,31 demonstrating that a conjugate of auristatin with a monoclonal antibody directed to the adhesion molecule E-selectin can inhibit the growth of prostate cancer cells.…”

Section: Dolastatin 10mentioning

confidence: 99%

Pharmaceutical applications of cyanobacteria—A review

Vijayakumar¹,

Menakha²

2015

Journal of Acute Medicine

172

105

View full text Add to dashboard Cite

Cyanobacteria are emerging as an important source of novel bioactive secondary metabolites. Recently, it has also been reported as a rich source of bioactive molecules such as apratoxins, lynbyabellin, and curacin A. Some compounds have exhibited very interesting results and successfully reached Phase II and Phase III clinical trials. Furthermore, cyanobacterial compounds hold a bright and promising future in scientific research and provide a great opportunity for new drug discovery. In 2005, a number of new technologies have led to the development of new miniaturized screens based on cell cultures, enzyme activities, and ligand receptor binding. The use of a computational method based on targeted metabolite data has provided additional insight into the ligand-based approach that employs conformational analysis of known ligands. This approach has implications for developing novel compounds for structure-based drug design. Hence, this review article mainly focuses on baseline information for promoting the use of cyanobacterial bioactive compounds as drugs for various dreadful human diseases, using the computational approach.

show abstract

Section: Dolastatin 10mentioning

confidence: 99%

Pharmaceutical applications of cyanobacteria—A review

Vijayakumar¹,

Menakha²

2015

Journal of Acute Medicine

172

105

View full text Add to dashboard Cite

show abstract

“…Albeit an IC 50 for enzyme or receptor inhibition is provided, no mechanism of action studies were reported at the time of publication: alotaketal C ( 224 ) [215]; aspergentisyl A ( 225 ) [216]; A. terreus butyrolactone ( 226 ) [217]; caulerpine ( 227 ) [218]; conicasterol F ( 228 ) [219]; D. avara sesquiterpene ( 229 ) [220]; D. gigantea sterols ( 230 , 231 ) [221]; dysidavarone A ( 232 ) [222]; galvaquinone B ( 233 ) [223]; halicloic acids A and B ( 234 , 235 ) [224]; isochromophilone XI ( 236 ) [225]; leucettamols A and B ( 237 , 238 ) [226]; manadosterol A ( 239 ) [227]; marilines A1 and A2 ( 240 , 241 ) [228]; methyl sarcotroate B ( 242 ) [229]; P. citrinum sorbicillinoid ( 243 ) [230]; phosphoiodyn A ( 244 ) [231]; purpuroines A and D ( 245 , 246 ) [232]; santacruzamate A ( 247 ) [233]; sarcophytonolide N ( 248 ) [234]; sargassumol ( 249 ) [235]; sesquibastadin 1 ( 250 ) [236]; S. glaucum cembranoids ( 251 – 253 ) [237]; symplocin A ( 254 ) [238]; tsitsikammamine A derivative ( 255 ) [239]; V. lanosa bromophenol ( 256 ) [240] ; and X. testudinaria fatty acid ( 257 ) [241]. …”

Section: Marine Compounds With Miscellaneous Mechanisms Of Actionmentioning

confidence: 99%

Marine Pharmacology in 2012–2013: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis, and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action

et al. 2017

View full text Add to dashboard Cite

The peer-reviewed marine pharmacology literature from 2012 to 2013 was systematically reviewed, consistent with the 1998–2011 reviews of this series. Marine pharmacology research from 2012 to 2013, conducted by scientists from 42 countries in addition to the United States, reported findings on the preclinical pharmacology of 257 marine compounds. The preclinical pharmacology of compounds isolated from marine organisms revealed antibacterial, antifungal, antiprotozoal, antituberculosis, antiviral and anthelmitic pharmacological activities for 113 marine natural products. In addition, 75 marine compounds were reported to have antidiabetic and anti-inflammatory activities and affect the immune and nervous system. Finally, 69 marine compounds were shown to display miscellaneous mechanisms of action which could contribute to novel pharmacological classes. Thus, in 2012–2013, the preclinical marine natural product pharmacology pipeline provided novel pharmacology and lead compounds to the clinical marine pharmaceutical pipeline, and contributed significantly to potentially novel therapeutic approaches to several global disease categories.

show abstract

“…10A), from a Symploca sp. collection also demonstrated selective and potent inhibitory activity against cathepsin E. 157 …”

Section: Mechanisms Of Action and Direct Cellular Targets Of Biologmentioning

confidence: 97%

Biological targets and mechanisms of action of natural products from marine cyanobacteria

2015

View full text Add to dashboard Cite

Marine cyanobacteria are an ancient group of organisms and prolific producers of bioactive secondary metabolites. These compounds are presumably optimized by evolution over billions of years to exert high affinity for their intended biological target in the ecologically relevant organism but likely also possess activity in different biological contexts such as human cells. Screening of marine cyanobacterial extracts for bioactive natural products has largely focused on cancer cell viability; however, diversification of the screening platform led to the characterization of many new bioactive compounds. Targets of compounds have oftentimes been elusive if the compounds were discovered through phenotypic assays. Over the past few years, technology has advanced to determine mechanism of action (MOA) and targets through reverse chemical genetic and proteomic approaches, which has been applied to certain cyanobacterial compounds and will be discussed in this review. Some cyanobacterial molecules are the most-potent-in-class inhibitors and therefore may become valuable tools for chemical biology to probe protein function but also be templates for novel drugs, assuming in vitro potency translates into cellular and in vivo activity. Our review will focus on compounds for which the direct targets have been deciphered or which were found to target a novel pathway, and link them to disease states where target modulation may be beneficial.

show abstract

Symplocin A, a Linear Peptide from the Bahamian Cyanobacterium Symploca sp. Configurational Analysis of N,N-Dimethylamino Acids by Chiral-Phase HPLC of Naphthacyl Esters

Cited by 37 publications

References 27 publications

Pharmaceutical applications of cyanobacteria—A review

Pharmaceutical applications of cyanobacteria—A review

Marine Pharmacology in 2012–2013: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis, and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action

Biological targets and mechanisms of action of natural products from marine cyanobacteria

Contact Info

Product

Resources

About